FindTrial
Sign In

Based on artificial intelligence and multi-group medical big data, prediction and clinical application of hepatocellular carcinoma benefiting population and target drug sensitive population after liver transplantation

Based on artificial intelligence and multi-group medical big data, prediction and clinical application of hepatocellular carcinoma benefiting population and target drug sensitive population after liver transplantation

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000036481
Enrollment
Unknown
Registered
2020-08-23
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Transplantation

Interventions

Case series:Nil

Sponsors

Department of General Surgery, Huashan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: From January 2014 to December 2022, all patients who received liver cancer transplantation and were pathologically confirmed as hepatocellular carcinoma in the General Surgery department of Huashan Hospital affiliated to Fudan University. Inclusion criteria: Hepatocellular carcinoma (HCC) confirmed by postoperative pathological findings

Exclusion criteria

Exclusion criteria: (1) the presence of extrahepatic metastasis; (2) Combined with other tumors; (3) Death within one month after surgery.

Design outcomes

Primary

MeasureTime frame
contrast-enhanced CT;—

Countries

China

Contacts

Public ContactWang Zhengxin

Huashan Hospital, Fudan University

wangzhengxin@huashan.org.cn+86 13901677081

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026